You guys have no idea how big this Lympro Test is. Most big pharma companies have failed to commercialize this product including Pfizer, J&J. They have spent $500 million in phase III but the trial failed. No big deal, it is pocket money.
Eli Lilly acquired Amyvid Test from Avid Radiopharmaceuticals for a whopping $800 million. ($300 million + $500 million in backend payments).It was not approved by FDA when they acquired. The Amyvid Test has lots of flaws despite it is FDA approved and yet it does not accurately diagnose patients with Alzeimer's disease.It costs patients lots of money through PET and MRI scans and after that further tests with limited accuracy. These machines are very expensive and are not readily available across US. Lympro is further ahead of Amyvid and is less expensive.
Read article link below for Amyvid Vs Lympro by Jason Napodano.
Next, Mark your Calendar for J P Morgan healthcare conference January 12-15 to be held in San Francisco.The Lympro will no longer be AMBS asset IMO because Gerald will be sitting on boatload of cash.
News 
Market Data 
Discover 
